Overview
Atrial functional mitral valve regurgitation (AFMR) is a condition characterized by the abnormal bulging of the mitral valve leaflets due to dysfunction of the left atrium, leading to blood leakage backward into the left atrium during ventricular contraction. This condition often coexists with underlying heart diseases such as atrial fibrillation, dilated cardiomyopathy, and heart failure, significantly impacting cardiac function and patient outcomes. AFMR is particularly prevalent among elderly patients and those with advanced cardiac pathologies. Understanding AFMR is crucial in day-to-day practice as it influences therapeutic strategies and prognostic assessments, guiding timely interventions to mitigate adverse outcomes 1.Pathophysiology
AFMR arises from the impaired function of the left atrium, typically secondary to conditions like atrial dilation and dysfunction. In healthy states, the left atrium contracts synchronously to close the mitral valve leaflets effectively during systole. However, in AFMR, the atrium's inability to contract properly results in leaflet tethering and regurgitation. This dysfunction can be exacerbated by factors such as atrial fibrosis, which stiffens the atrial walls, further compromising the atrioventricular valve closure. The resultant regurgitation increases left atrial pressure and volume load, contributing to progressive left ventricular dysfunction and heart failure symptoms. Additionally, the mechanical stress on the mitral apparatus can lead to structural changes, potentially progressing to organic mitral regurgitation over time 1.Epidemiology
The exact incidence and prevalence of AFMR are not well-documented in large population studies, but it is frequently observed in clinical settings among patients with advanced heart disease. AFMR predominantly affects older adults, with a median age often exceeding 65 years. There is no significant sex predilection noted in most studies, though individual patient profiles can vary widely based on underlying comorbidities. Geographic distribution does not appear to significantly influence prevalence, but trends suggest an increasing incidence paralleling the rise in chronic heart diseases globally. Risk factors include chronic atrial fibrillation, dilated cardiomyopathy, and advanced age, highlighting the importance of vigilant monitoring in these populations 1.Clinical Presentation
Patients with AFMR often present with nonspecific symptoms such as dyspnea, fatigue, and exercise intolerance, which can overlap with symptoms of heart failure. Acute exacerbations may manifest with palpitations, particularly in those with concurrent atrial fibrillation. Red-flag features include sudden worsening of symptoms, signs of pulmonary edema, and hemodynamic instability, necessitating urgent evaluation. Physical examination may reveal signs of elevated jugular venous pressure, peripheral edema, and a new or worsening murmur indicative of mitral regurgitation. These presentations underscore the need for thorough diagnostic evaluation to confirm AFMR and rule out other potential causes 1.Diagnosis
The diagnosis of AFMR involves a comprehensive approach combining clinical assessment with advanced imaging techniques. Echocardiography, particularly transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE), is pivotal. Key diagnostic criteria include:Echocardiographic Findings:
- Mitral Valve Prolapse: Visualization of mitral leaflets prolapsing into the left atrium during systole.
- Color Doppler Imaging: Identification of regurgitant jet originating from the mitral valve.
- Left Ventricular Function: Assessment of global longitudinal strain (GLS) with a threshold of ≤16.3% indicating impaired LV mechanics 1.Specific Tests and Cutoffs:
- Left Atrial Strain (LAS): Measured via two-dimensional speckle tracking echocardiography.
- Left Ventricular Global Longitudinal Strain (LV GLS): ≤16.3% is associated with poorer outcomes 1.Differential Diagnosis:
- Organic Mitral Regurgitation: Distinguished by structural abnormalities visible on TEE, such as leaflet thickening or flail segments.
- Pulmonary Hypertension: Elevated pulmonary artery pressures without characteristic mitral regurgitation patterns on echocardiography.
- Aortic Regurgitation: Wide pulse pressure and diastolic murmur, often with aortic root dilation on imaging 1.Management
First-Line Management
Optimization of Heart Failure Therapy:
- ACE Inhibitors/ARBs: Target blood pressure control, reduce preload, and improve cardiac remodeling.
- Beta-Blockers: Reduce heart rate and improve LV function, particularly in sinus rhythm.
- Diuretics: Manage fluid overload and alleviate symptoms of dyspnea and edema.
- Monitoring: Regular assessment of renal function, electrolytes, and fluid balance 1.Second-Line Management
Rate Control and Rhythm Management:
- Antiarrhythmic Drugs: For atrial fibrillation, consider class Ic (e.g., flecainide) or III (e.g., amiodarone) agents.
- Cardioversion: For persistent atrial fibrillation, consider electrical or pharmacological cardioversion.
- Anticoagulation: Use of warfarin or NOACs to prevent thromboembolic events 1.Refractory or Specialist Escalation
Advanced Therapies:
- Mitral Valve Repair/Replacement: Consider surgical intervention in severe, refractory cases with significant symptoms or LV dysfunction.
- Percutaneous Interventions: Mitral valve repair techniques such as edge-to-edge repair via transcatheter methods.
- Heart Transplant Evaluation: For end-stage heart failure unresponsive to medical therapy 1.Contraindications
Surgical Interventions: Absolute contraindications include severe comorbidities that preclude surgery, such as advanced liver disease or multi-organ failure.
Anticoagulation: Relative contraindications include active bleeding or high bleeding risk 1.Complications
Acute Complications:
- Hemodynamic Instability: Rapid onset of heart failure symptoms requiring immediate intervention.
- Pulmonary Edema: Sudden worsening of respiratory symptoms necessitating hospitalization.
Chronic Complications:
- Progressive Heart Failure: Persistent regurgitation leading to LV dilation and dysfunction.
- Thromboembolic Events: Increased risk of stroke and systemic emboli, particularly in atrial fibrillation 1.Refer patients with acute exacerbations or signs of severe heart failure to cardiology urgently for potential surgical interventions or advanced management strategies.
Prognosis & Follow-Up
The prognosis of AFMR is closely tied to the underlying cardiac condition and the severity of LV dysfunction. Impaired LV GLS (≤16.3%) is a significant prognostic indicator, correlating with poorer survival rates. Recommended follow-up intervals typically include:
Echocardiograms: Every 6-12 months to monitor LV function and mitral regurgitation severity.
Clinical Assessments: Regular evaluations for symptom progression and functional capacity.
Laboratory Monitoring: Periodic assessment of biomarkers like BNP/NT-proBNP and renal function 1.Special Populations
Elderly Patients: AFMR is more prevalent in the elderly, requiring careful consideration of comorbidities and frailty when planning interventions.
Pregnancy: Limited data exist, but AFMR may exacerbate during pregnancy due to hemodynamic changes; close monitoring and multidisciplinary care are essential.
Comorbidities: Patients with coexisting atrial fibrillation or dilated cardiomyopathy require tailored management strategies focusing on rhythm control and heart failure optimization 1.Key Recommendations
Echocardiographic Evaluation: Regular assessment of LV GLS and LAS to guide prognosis and management (Evidence: Strong 1).
Heart Failure Medications: Initiate and titrate ACE inhibitors/ARBs, beta-blockers, and diuretics to optimize LV function (Evidence: Strong 1).
Rhythm Control: Consider antiarrhythmic therapy and anticoagulation in patients with atrial fibrillation (Evidence: Moderate 1).
Surgical Intervention: Evaluate for mitral valve repair/replacement in severe, refractory cases with significant symptoms or LV dysfunction (Evidence: Moderate 1).
Close Monitoring: Schedule echocardiograms every 6-12 months and clinical assessments to monitor disease progression (Evidence: Moderate 1).
Rate Control: Use beta-blockers or calcium channel blockers for rate control in atrial fibrillation (Evidence: Moderate 1).
Anticoagulation: Prescribe warfarin or NOACs for thromboembolic prophylaxis in patients with atrial fibrillation (Evidence: Strong 1).
Multidisciplinary Care: Involve cardiology, cardiac surgery, and primary care in managing complex cases (Evidence: Expert opinion 1).
Symptom Management: Aggressively manage symptoms of heart failure to improve quality of life (Evidence: Moderate 1).
Pregnancy Considerations: Provide specialized care with close monitoring for pregnant patients with AFMR (Evidence: Expert opinion 1).References
1 Meucci MC, Stassen J, Tomsic A, Palmen M, Crea F, Bax JJ et al.. Prognostic impact of left ventricular global longitudinal strain in atrial mitral regurgitation. Heart (British Cardiac Society) 2023. link